On May 20, BrainAurora-B fell 5.12% in regular trading, trading at HK$3.89/share, with trading volume of HK$129 million. The decline comes after the stock surged as much as 50% in the prior session.

The previous session's rally was driven by China officially launching its first 128-channel fully implanted brain-computer interface (BCI) system multi-center clinical trial on May 18. The trial, led by Capital Medical University-affiliated Beijing Tiantan Hospital with 11 medical institutions participating, plans to enroll 32 patients within six months. The milestone marks China's self-developed fully invasive BCI technology entering the clinical translation stage, targeting rehabilitation for quadriplegic patients. The system features cortical implantable flexible electrodes using ultra-thin biocompatible materials with high spatiotemporal resolution for single-neuron action potential capture.

Institutions have noted that the BCI industry is at a critical juncture transitioning from laboratory breakthroughs to commercial deployment, with market scale potentially expanding from tens of billions to hundreds of billions in the long term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)